## Boehringer Ingelheim Launches Cyltezo Pen, a Biosimilar to Humira, in the US
![Boehringer Ingelheim Cyltezo Pen](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2023/07/shutterstock_1849560364.jpg)
Boehringer Ingelheim’s new autoinjector pen administering Cyltezo (adalimumab-adbm) is now available to patients living with chronic inflammatory diseases in the US.
### The Cyltezo Pen: A Biosimilar to Humira
– The Cyltezo pen autoinjector is a biosimilar to AbbVie’s blockbuster drug Humira.
– It received approval from the US Food and Drug Administration (FDA) in May 2023.
– Boehringer Ingelheim originally received FDA approval for the drug in 2017 and further approval as an interchangeable biosimilar in 2021.
### Options for Patients
– The 40mg/0.8ml pre-filled Cyltezo Pen will be offered in two, four, and six-pack options.
### Challenging Humira’s Monopoly
– AbbVie’s Humira has enjoyed a prosperous monopoly in the adalimumab market, generating $21.2bn in global sales in 2022.
– With several biosimilars expected to flood the market in 2023 and the loss of exclusivity, AbbVie anticipates a 37% decline in sales of Humira in 2023.
– Competitors, such as Organon and Samsung Bioepsis, have launched an autoinjector pen called Hadlima, which is 85% cheaper than Humira.
### Boehringer Ingelheim’s Competitive Advantage
– Boehringer Ingelheim’s Cyltezo is currently the only approved interchangeable biosimilar to Humira.
– The drug has undergone Phase III comparative clinical trials in rheumatoid arthritis, plaque psoriasis, and Crohn’s disease.
### Positive Reactions from Patient Communities
– Patient advocacy groups, such as the Arthritis Foundation and the Crohn’s & Colitis Foundation, welcome adalimumab biosimilars like Cyltezo as new treatment options for chronic inflammatory conditions.
In conclusion, Boehringer Ingelheim’s launch of the Cyltezo Pen in the US provides patients with a new biosimilar option for the treatment of chronic inflammatory diseases. With the market opening up to competition, patients can benefit from increased access to critical biologic medicines at potentially lower costs.